Cullinan Therapeutics Begins Phase 2 Trial of CLN-049 for Relapsed AML
Cullinan Therapeutics has dosed the first patient in a pivotal Phase 2 study of CLN-049, a novel FLT3 T cell engager targeting relapsed or refractory acute myeloid leukemia.
Cullinan Therapeutics announced Wednesday that the first patient has been enrolled and dosed in its planned registrational Phase 2 clinical trial evaluating CLN-049, an investigational FLT3-targeting T cell engager, in adults with relapsed or refractory acute myeloid leukemia (AML). The Cambridge, Massachusetts-based biopharmaceutical company described the milestone as a pivotal step in the drug's development path.
CLN-049 is designed to engage T cells to attack leukemia cells carrying the FLT3 receptor, a target frequently implicated in AML. Relapsed or refractory AML represents a particularly difficult-to-treat patient population with limited therapeutic options and poor prognosis, making new treatment approaches a significant area of unmet medical need.
Read more X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures →
Cullinan, which trades on the Nasdaq under the ticker CGEM, positions itself as a clinical-stage company focused on developing first- or best-in-class, disease-modifying T cell engagers across both autoimmune diseases and oncology. The Phase 2 study of CLN-049 marks one of the company's most advanced oncology programs to date.
The initiation of a registrational-intent study signals that Cullinan believes early clinical data for CLN-049 may be sufficiently compelling to support a potential future regulatory submission, though no approval timeline has been announced. Analysts and investors in the biotech sector typically view first-patient-dosed announcements in pivotal trials as meaningful de-risking events for clinical-stage companies.
Continue reading at GlobeNewswire - Industry News on Financial Services.
